A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients

medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…

AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.

• AI pathomics flags immunotherapy responders in lung cancer (4)
• Challenges deploying AI in lung cancer diagnosis and care (3)
• Evolving lung cancer immunotherapy trials and biomarker debates (4)
• All Other Stories

AI pathomics flags immunotherapy responders in lung cancer

Challenges deploying AI in lung cancer diagnosis and care

Evolving lung cancer immunotherapy trials and biomarker debates

All Other Stories